Trial Profile

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omega-3 carboxylic acids (Primary) ; HMG-CoA reductase inhibitors
Indications Cardiovascular disorders; Hypertriglyceridaemia
Focus Registrational; Therapeutic Use
Acronyms STRENGTH
Sponsors AstraZeneca

Most Recent Events

15 Nov 2020 Primary endpoint (The primary outcome measure is the time to the first occurrence of any component of the composite of MACE.) has not been met.
15 Nov 2020 Results published in the JAMA: the Journal of the American Medical Association.
30 Jul 2020 This trial has been completed in Belgium, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com